You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
眾生藥業(002317.SZ)子公司獲得澳大利亞專利證書
格隆匯 11-15 16:53

格隆匯11月15日丨眾生藥業(002317.SZ)公佈,近日,公司控股子公司廣東眾生睿創生物科技有限公司(“眾生睿創”)收到澳大利亞專利局(IP Australia)頒發的專利證書。

專利名稱:Pyrrolidine derivative serving as PPAR agonist(作為PPAR激動劑的吡咯烷衍生物);專利申請日:2017年07月12日;專利權期限:自申請日起二十年。

該專利是公司控股子公司眾生睿創在NASH領域佈局的第二個創新藥ZSP0678項目的化合物專利,屬於該項目的核心專利。ZSP0678是一種過氧化物酶體增殖物激活受體(PPAR)激動劑,是具有明確作用機制的用於治療NASH的潛在藥物,目前ZSP0678項目已獲得臨牀試驗通知書,臨牀試驗的相關工作正在按計劃推進。

此次ZSP0678項目化合物專利獲得澳大利亞專利局的授權,是該項目化合物專利獲得的首個專利授權,ZSP0678項目的全球知識產權保護體系逐漸完善。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account